[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 200, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1025727, "exercisedValue": 0, "unexercisedValue": 207573}, {"maxAge": 1, "name": "Dr. Chrystal U. Louis M.D., M.P.H.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 550125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 54, "title": "Chief Legal & Strategy Officer and Company Secretary", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 657200, "exercisedValue": 0, "unexercisedValue": 85247}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ray  Lockard M.B.A.", "title": "Senior Vice President & Head of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Murray", "title": "Senior VP & Head of Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.44, "open": 1.42, "dayLow": 1.37, "dayHigh": 1.44, "regularMarketPreviousClose": 1.44, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.37, "regularMarketDayHigh": 1.44, "payoutRatio": 0.0, "beta": 1.057, "forwardPE": -1.0697675, "volume": 531912, "regularMarketVolume": 531912, "averageVolume": 553326, "averageVolume10days": 1159460, "averageDailyVolume10Day": 1159460, "bid": 1.33, "ask": 1.42, "bidSize": 1, "askSize": 1, "marketCap": 78095024, "fiftyTwoWeekLow": 1.02, "fiftyTwoWeekHigh": 9.29, "priceToSalesTrailing12Months": 17.66456, "fiftyDayAverage": 1.4132, "twoHundredDayAverage": 3.425575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -76556936, "profitMargins": 0.0, "floatShares": 40710731, "sharesOutstanding": 52314000, "sharesShort": 1793660, "sharesShortPriorMonth": 2025238, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0317, "heldPercentInsiders": 0.0023999999, "heldPercentInstitutions": 0.87882006, "shortRatio": 3.46, "shortPercentOfFloat": 0.038399998, "impliedSharesOutstanding": 5143130, "bookValue": 3.714, "priceToBook": 0.37156704, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -131484000, "trailingEps": -1.08, "forwardEps": -1.29, "enterpriseToRevenue": -17.317, "enterpriseToEbitda": 0.562, "52WeekChange": -0.84210527, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 1.38, "targetHighPrice": 12.0, "targetLowPrice": 3.0, "targetMeanPrice": 9.0, "targetMedianPrice": 10.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 251688992, "totalCashPerShare": 4.448, "ebitda": -136166000, "totalDebt": 97037000, "quickRatio": 8.441, "currentRatio": 8.547, "totalRevenue": 4421000, "debtToEquity": 46.164, "revenuePerShare": 0.078, "returnOnAssets": -0.30446, "returnOnEquity": -0.78929, "grossProfits": -5356000, "freeCashflow": -77268376, "operatingCashflow": -119141000, "revenueGrowth": 2.836, "grossMargins": -1.21149, "ebitdaMargins": 0.0, "operatingMargins": -16.69737, "financialCurrency": "USD", "symbol": "TCRX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1748036663, "regularMarketTime": 1748030401, "exchange": "NGM", "messageBoardId": "finmb_583057578", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1626442200000, "fiftyTwoWeekHighChangePercent": -0.8514532, "fiftyTwoWeekChangePercent": -84.210526, "epsTrailingTwelveMonths": -1.08, "epsForward": -1.29, "epsCurrentYear": -1.23471, "priceEpsCurrentYear": -1.1176714, "fiftyDayAverageChange": -0.033200026, "fiftyDayAverageChangePercent": -0.0234928, "twoHundredDayAverageChange": -2.0455751, "twoHundredDayAverageChangePercent": -0.59714794, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-16", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "postMarketChangePercent": -2.16666, "postMarketPrice": 1.3501, "postMarketChange": -0.0299, "regularMarketChange": -0.060000062, "regularMarketDayRange": "1.37 - 1.44", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 553326, "fiftyTwoWeekLowChange": 0.36, "fiftyTwoWeekLowChangePercent": 0.3529412, "fiftyTwoWeekRange": "1.02 - 9.29", "fiftyTwoWeekHighChange": -7.91, "regularMarketChangePercent": -4.166671, "regularMarketPrice": 1.38, "displayName": "TScan Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]